Search

Diabetes is not so much being cured as it is being surrounded. Researchers are coming at this common disorder from a number of different perspectives, and some of their discoveries [...]

To reduce health inequalities and improve access to health care services, the Mexican government embarked on a major health care reform starting in 2001. Seguro Popular (People's Health Insurance; SP) [...], Objective. To examine the impact of Seguro Popular (Mexican social health insurance for the poor; SP) on diabetes and hypertension care, intermediate process indicators for older adults (>50 years): pharmacological treatment, blood glucose tests, the use of complementary and alternative medicine (CAM), and adherence to their nutrition and exercise program. (CAM was defined as products or practices that were not part of the medical standard of care.) Data Sources/Study Setting. Repeated cross-sectional surveys from Encuesta National de Salud y Nutrition (Mexican Health and Nutrition Survey, ENSANUT), a nationally representative health and nutrition survey sampling N = 45,294 older adults in 2000, N = 45,241 older adults in 2005-2006, and N = 46,277 older adults in 2011-2012. Study Design. Fixed-effects instrumental variable (FE-IV) repeated cross-sectional at the individual level with municipality fixed-effects estimation was performed. Principal Findings. We found a marginally significant effect of SP on the use of insulin and oral agents (40 percentage points). Contrary to that expected, no other significant differences were found for diabetes or hypertension treatment and care indicators. Conclusions. Social health insurance for the poor improved some but not all health care process indicators among diabetic and hypertensive older people in Mexico. Key Words. Health insurance, health care access, Seguro Popular, diabetes, hypertension

The expanded role of community retail pharmacists as key participants in health care teams is perhaps no better demonstrated than in diabetes care, a chronic disease state in which pharmacists [...]

As pharmacists seek greater recognition as health care service providers and an expanded scope of practice, their value is arguably demonstrated nowhere more than in diabetes care. Pharmacists can be [...]

DarioHealth (DRIO) announced that the United States FDA has granted Pre-market Notification 510(k) clearance for the company's Lightning-enabled version of the acclaimed Dario Blood Glucose Monitoring System which enables the [...]

Medtronic announced it received U.S. Food and Drug Administration approval for its Guardian Connect continuous glucose monitoring system, for people with diabetes ages 14 to 75 years. The Guardian Connect [...]

WaveForm Technologies, a developer of products for continuous glucose monitoring and a wholly owned subsidiary of AgaMatrix Holdings, announced that the Patent Trial and Appeal Board, or PTAB, of the [...]

For many years, much of the research and many advances in type 2 diabetes treatment focused on ways to keep patients' blood sugar levels from going too high to protect [...]

OBJECTIVE--To assess whether intermittent real-time continuous glucose monitoring (CGM) improves glycemic control and pregnancy outcome in unselected women with pregestational diabetes. RESEARCH DESIGN AND METHODS--A total of 123 women with [...]

OBJECTIVE--Hypoglycemia is associated with increased mortality in hospitalized patients. We investigated the relationship between spontaneous hypoglycemia versus insulin-associated hypoglycemia and mortality in hospitalized patients. RESEARCH DESIGN AND METHODS--Data for this [...]

The usefulness of self-monitoring of blood glucose (SMBG) requires patients with diabetes to be competent and confident in their ability to carry out glucose testing and interpret its results to [...]

OBJECTIVE--Cross-sectional studies link both depressive symptoms (DS) and diabetes-related distress (DRD) to diabetes self-management and/or glycemic control. However, longitudinal studies of these variables are rare, and their results are somewhat [...]

OBJECTIVE--To test models of unidirectional and bidirectional change between treatment adherence and glycemic control in youth with type 1 diabetes. RESEARCH DESIGN AND METHODS--We conducted a 2-year longitudinal, multisite study [...]

OBJECTIVE--To determine exposure to hyper- and hypoglycemia using blinded continuous glucose monitoring (CGM) profiles in youth with type 1 diabetes (T1D) with residual [beta]-cell function during the first year of [...]

OBJECTIVE--Continuous glucose monitoring (CGM) has been demonstrated to improve glycemic control in adults with type 1 diabetes but less so in children. We designed a study to assess CGM benefit [...]

OBJECTIVE--To assess the occurrence of white coat adherence in families with children who have type 1 diabetes. RESEARCH DESIGN AND METHODS--Blood glucose data were downloaded from meters of 72 children, [...]

OBJECTIVE--The A1C-Derived Average Glucose (ADAG) study demonstrated a linear relationship between [HbA.sub.1c] and mean plasma glucose (MPG). As glucose variability (GV) may contribute to glycation, we examined the association of [...]

OBJECTIVE--The effect of glycemic variability (GV) on cardiovascular risk has not been fully clarified in type 2 diabetes. We evaluated the effect of GV, blood pressure (BP), and oxidative stress [...]

OBJECTIVE--To investigate the effect of 4 weeks of treatment with liraglutide on insulin dose and glycemic control in type 1 diabetic patients with and without residual β-cell function. RESEARCH DESIGN [...]

The ultimate goal of diabetes technology is to create an artificial pancreas, or closed-loop system. In the early 1970s, the first prototypes became available (1). Although recent advances are promising, [...]

OBJECTIVE--To assess the impact of continuous glucose monitoring on hypoglycemia in people with type 1 diabetes. RESEARCH DESIGN AND METHODS--In this randomized, controlled, multicenter study, 120 children and adults on [...]

OBJECTIVE--To compare use of continuous glucose monitoring in subjects with type 1 diabetes on multiple daily injection (MDI) therapy versus continuous subcutaneous insulin infusion (CSII) therapy for 6 months. RESEARCH [...]

OBJECTIVE--There is no general agreement regarding the use of the first or second drop of blood for glucose monitoring. This study investigated whether capillary glucose concentrations, as measured in the [...]

OBJECTIVE--To examine the effect of intravenous iron and erythropoietin-stimulating agents (ESAs) on glycemic control and A1C of patients with diabetes and chronic kidney disease (CKD). RESEARCH DESIGN AND METHODS--This was [...]

Repeated blood glucose monitoring is a mainstay of modern diabetes management, with type 1 diabetes patients testing blood glucose concentrations up to 10 times a day and type 2 diabetes [...]

Ghrelin has gained considerable attention over the last decade for its unique role in regulating mealtime hunger and lipid metabolism, as well as short- and long-term energy homeostasis (1-3). It [...], OBJECTIVE--The orexigenic gut hormone ghrelin and its receptor are present in pancreatic islets. Although ghrelin reduces insulin secretion in rodents, its effect on insulin secretion in humans has not been established. The goal of this study was to test the hypothesis that circulating ghrelin suppresses glucose-stimulated insulin secretion in healthy subjects. RESEARCH DESIGN AND METHODS--Ghrelin (0.3, 0.9 and 1.5 nmol/kg/h) or saline was infused for more than 65 min in 12 healthy patients (8 male/4 female) on 4 separate occasions in a counterbalanced fashion. An intravenous glucose tolerance test was performed during steady state plasma ghrelin levels. The acute insulin response to intravenous glucose (AIRg) was calculated from plasma insulin concentrations between 2 and 10 min after the glucose bolus. Intravenous glucose tolerance was measured as the glucose disappearance constant (Kg) from 10 to 30 min. RESULTS--The three ghrelin infusions raised plasma total ghrelin concentrations to 4-, 15-, and 23-fold above the fasting level, respectively. Ghrelin infusion did not alter fasting plasma insulin or glucose, but compared with saline, the 0.3, 0.9, and 1.5 nmol/kg/h doses decreased AIRg (2,152 ± 448 vs. 1,478 ± 2,889, 1,419 ± 275, and 1,120 ± 174 pmol/1) and Kg (0.3 and 1.5 nmol/kg/h doses only) significantly (P < 0.05 for all). Ghrelin infusion raised plasma growth hormone and serum cortisol concentrations significantly (P < 0.001 for both), but had no effect on glucagon, epinephrine, or norepinephrine levels (P = 0.44, 0.74, and 0.48, respectively). CONCLUSIONS--This is a robust proof-of-concept study showing that exogenous ghrelin reduces glucose-stimulated insulin secretion and glucose disappearance in healthy humans. Our findings raise the possibility that endogenous ghrelin has a role in physiologic insulin secretion, and that ghrelin antagonists could improve β-cell function. Diabetes 59:2145-2151, 2010

OBJECTIVE--The purpose of this study was to develop an advanced algorithm that detects pending hypoglycemia and then suspends basal insulin delivery. This approach can provide a solution to the problem [...]

OBJECTIVE--To evaluate an algorithm guiding responses of continuous subcutaneous insulin infusion (CSII)-treated type 1 diabetic patients using real-time continuous glucose monitoring (RT-CGM). RESEARCH DESIGN AND METHODS--Sixty CSII-treated type 1 diabetic [...]

Purpose. To determine whether the association between diabetes-specific family conflict and self-monitoring of blood glucose (SMBG) frequency is mediated by diabetes self-efficacy. Methods. A total of 276 adolescents with type [...]

OBJECTIVE--To update and validate a diabetes-specific screening tool for disordered eating (the Diabetes Eating Problem Survey [DEPS]) in contemporary youth with type 1 diabetes. RESEARCH DESIGN AND METHODS--A total of [...]

OBJECTIVE--To evaluate the impact of real-time continuous glucose monitoring (CGM) on glycemic control and risk of hypoglycemia in critically ill patients. RESEARCH DESIGN AND METHODS--A total 124 patients receiving mechanical [...]

OBJECTIVE-- To investigate the relationship among A1C, fasting plasma glucose (FPG), and 2-h postload plasma glucose in the Dutch general population and to evaluate the results of using A1C for [...]

OBJECTIVE--To determine whether continuous glucose monitoring (CGM) is effective in the management of type 1 diabetes when implemented in a manner that more closely approximates clinical practice. RESEARCH DESIGN AND [...]

Tandem Diabetes Care announced its submission of a medical device license application to Health Canada to market its t:slim X2 Insulin Pump with Dexcom G5 Mobile continuous glucose monitoring integration1. [...]

DarioHealth (DRIO) announced the launch and first sales of its Dario Blood Glucose Monitoring System on Amazon (AMZN). DarioHealth is committed to offering people with diabetes more access to its [...]

Gluco-Chaser reported that its disposable strip BGM (blood glucose monitoring) prototype sensor with non-enzymatic electrochemistry achieved a 5-second glucose reading from human whole blood (Applied Materials Today, 10, 24, March [...]

2018 FEB 17 (NewsRx) -- By a News Reporter-Staff News Editor at Obesity, Fitness & Wellness Week -- Investigators publish new report on Nutritional and Metabolic Diseases and Conditions - [...]

DarioHealth announced it has partnered with the Diabetes and Endocrinology Consultants of Pennsylvania, the clinical practice of Dr. Alan Schorr and Dr. Arvind Cavale, with expertise in incorporating state of [...]

DarioHealth has entered into an agreement with a pharmaceutical company conducting a clinical study for a new drug related to managing diabetes. The pharmaceutical company is seeking FDA clearance for [...]